Following the recommendations of an independent Data Monitoring Committee, Novo Nordisk has halted a Phase III kidney outcomes study of semaglutide ahead of schedule due to strong efficacy signals.
At the six-month follow-up, about 40% of patients treated with Newron Pharmaceuticals’ evenamide improved so much that they no longer meet the Phase II study’s original eligibility criteria.
Patients treated with Xenon Pharmaceuticals’ investigational potassium channel opener XEN1101 experienced a significant and dose-dependent reduction in seizure frequency.
Akero Therapeutics said on Tuesday its lead drug missed the main goal in a mid-stage trial treatment of patients with a severe type of fatty liver disease, sending its shares tumbling 63% in premarket trading.
For Novo Nordisk, Ozempic is the game changer that has propelled the company to new heights, but mastering the supplies of its semaglutide drugs, especially Wegovy, is the current challenge.
As the COVID-19 pandemic continues to recede, the top pharma companies intensified their focus into areas such as cancer and metabolic diseases to build up their pipelines, and their growth prospects, for the future.
With Humira finally losing exclusivity and market share, a new generation of autoimmune drugs is entering the spotlight at AbbVie.
With the settlement of a big acquisition behind them and a strong portfolio of therapeutics that continues to expand, hopes for smooth sailing are on the horizon.
For AstraZeneca, the approval of Enhertu last year marked one of the high points in the company’s scientific program.
Boehringer Ingelheim is concentrating on expanding its pipeline beyond Jardiance and other key products.